全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol

DOI: 10.4236/oalib.1103807, PP. 1-13

Subject Areas: Clinical Medicine

Keywords: Acute Lymphoblastic Leukemia, Cytopenia, Febrile Neutropenia, Transfusion Requirement

Full-Text   Cite this paper   Add to My Lib

Abstract

The most common childhood cancer is acute lymphoblastic leukemia (ALL). Chemotherapy-associated hematological toxicity is well-known; however, there are few studies on hematologic toxicity incidence in children with ALL. We investigated the severity and incidence of hematologic toxicity during intense chemotherapy processes in children treated with ALL IC-BFM 2009 protocol. The study included 41 leukemic children in standard (SR) and intermediate risk (IR) groups treated between 2011 and 2015. During the induction period, the incidence of grade 4 toxicity in neutrophil count was 60%; the incidence of grade ≥ 3 toxicity in hemoglobin level was 34%; and the incidence of grade ≥ 3 toxicity in the platelet count was 51%. Deep neutropenia duration was 36.6 ± 12.7 (18-68) days during the induction. 53% of the febrile neutropenic (FEN) episodes developed during the induction period. There were no statistical differences between SR and IR risk groups with respect to hemogram values deep neutropenia duration and the number of FEN episodes (p > 0.05, all). There was a positive correlation between the number of FEN episodes and duration of neutropenia. During the induction, the mean neutrophil count remained between 0.5-1 × 109/L. FEN episodes most commonly developed during the induction phase.

Cite this paper

Ozdemir, Z. C. , Kar, Y. D. , Turhan, A. B. and Bor, O. (2017). Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol. Open Access Library Journal, 4, e3807. doi: http://dx.doi.org/10.4236/oalib.1103807.

References

[1]  SEER Cancer Statistics Review, National Cancer Institute. Bethesda, MD.
[2]  Gaynon, P.S., Angiolillo, A.L., Carroll, W.L., et al. (2010) Long-Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983-2002: A Children’s Oncology Group Report. Leukemia, 24, 285-297.
https://doi.org/10.1038/leu.2009.262
[3]  Badr, M., Hassan, T., Sakr, H., et al. (2016) Chemotherapy-Induced Neutropenia among Pediatric Cancer Patients in Egypt: Risks and Consequences. Molecular and Clinical Oncology, 5, 300-306.
[4]  Castagnola, E., Fontana, V., Caviglia, I., et al. (2007) A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 45, 1296-1304.
https://doi.org/10.1086/522533
[5]  Yilmaz, S., Oren, H., Demirciogu, F., et al. (2008) Assessment of Febrile Neutropenia Episodes in Children with Acute Leukemia Treated with BFM Protocols. Pediatric Hematology and Oncology, 25, 195-204.
https://doi.org/10.1080/08880010801938231
[6]  Ranan, Z.A., Rabbani, M.W., Sheikh, M.A., et al. (2009) Outcome of Childhood Acute Lymphoblastic Leukemia after Induction Therapy 3 Years Experience at e Single Paediatric Oncology Centre. Journal of Ayub Medical College Abbottabad, 21, 150-153.
[7]  Ozdemir, N., Tüysüz, G., Celik, N., et al. (2016) Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia: Single Center Experience. Turkish Pediatric Arsivi, 51, 79-86.
https://doi.org/10.5152/TurkPediatriArs.2016.2757
[8]  Li, S.D., Chen, Y.B., Li, Z.G., et al. (2015) Infections during Induction Therapy of Protocol CCLG 2008 in Childhood Acute Lymphoblastic Leukemia: A Single Center Experience with 256 Cases in China. Chinese Medical Journal, 128, 472-476.
https://doi.org/10.4103/0366-6999.151085
[9]  A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia. Final Version of Therapy Protocol from August-14-2009.
[10]  U.S. National Institutes of Health. National Cancer Institute CTEP CTCAE v3.0. 2011.
http://ctep.cancer.gov/reporting/ctc.html
[11]  Crawford, J., Dale, D.C. and Lyman, G.H. (2004) Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer, 100, 228-237.
https://doi.org/10.1002/cncr.11882
[12]  Bodey, G.P., Buckley, M., Sathe, Y.S., et al. (1966) Quantitative Relationships between Circulating Leukocytes and Infection in Patients with Acute Leukemia. Annals of Internal Medicine, 64, 328-340.
https://doi.org/10.7326/0003-4819-64-2-328
[13]  Lyman, G.H., Kuderer, N.M. and Balducci, L. (2002) Cost-Benefit Analysis of Granulocyte Colony-Stimulating Factor in the Management of Elderly Cancer Patients. Current Opinion in Hematology, 9, 207-214.
https://doi.org/10.1097/00062752-200205000-00006
[14]  Weycker, D., Barron, R., Kartashov, A., et al. (2014) Incidence, Treatment and Consequences of Chemotherapy-Induced Febrile Neutropenia in the Inpatient and Outpatient Settings. Journal of Oncology Pharmacy Practice, 20, 190-198.
https://doi.org/10.1177/1078155213492450
[15]  Buffler, P.A., Kwan, M.L., Reynods, P., et al. (2005) Environmental and Genetic Risk Factors for Childhood Leukemia: Appraising the Evidence. Cancer Investigation, 23, 60-75.
https://doi.org/10.1081/CNV-46402
[16]  Biswal, S. and Godnaik, C. (2013) Incidence and Management of Infections in Patients with Acute Leukemia Following Chemotherapy in General Wards. Ecancermedicalscience, 7, 310.
[17]  Ribera, J.M., Oriol, A., Sanz, M.A., et al. (2008) Comparison of the Results of the Treatment of Adolescents and Young Adults with Standard Risk Acute Lymphoblastic Leukemia with the Programa Espanol de Tratamiento en Hematologia Pediatric Based Protocol ALL-96. Journal of Clinical Oncology, 28, 1843-1849.
https://doi.org/10.1200/JCO.2007.13.7265
[18]  Tang, J.Y., Gu, L.J., Xue, H.L., et al. (2009) Report on Induction Efficacy of Protocol ALL-2005 and Middle Term Follow-Up of 158 Cases of Childhood Acute Lymphoblastic Leukemia. Chinese Journal of Hematology, 30, 289-293.
[19]  Nakamura, S., Gelber, R.D. and Blattner, S. (2000) Long-Term Follow-Up and Infectious Complications of Therapy for Acute Lymphoblastic Leukemia in Children. International Journal of Pediatric Hematology/Oncology, 6, 321-330.
[20]  Cooper, S.L. and Brown, P.A. (2015) Treatment of Pediatric Acute Lymphoblastic Leukemia. Pediatric Clinics of North America, 62, 61-73.
[21]  Burnett, A.K., Russel, N.H., Hills, R.K., et al. (2015) A Randomized Comparison Daunorubicin 90 mg/m2 vs. 60 mg/m in AML Induction: Results from the UKNCRIAML 17 Trial in 1206 Patients. Blood, 125, 3878-3885.
https://doi.org/10.1182/blood-2015-01-623447
[22]  Miller, C.B., Jones, R.J., Piantadosi, S., et al. (1990) Decreased Erythropoietin Response in Patients with the Anemia of Cancer. The New England Journal of Medicine, 322, 1689-1692.
https://doi.org/10.1056/NEJM199006143222401
[23]  Groopman, J.E. and Itri, L.M. (1999) Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. Journal of the National Cancer Institute, 91, 1616-1634.
https://doi.org/10.1093/jnci/91.19.1616
[24]  Wu, Y., Aravind, S., Ranganathan, G., et al. (2009) Anemia and Thrombocytopenia in Patients Undergoing Chemotherapy for Solid Tumors: A Descriptive Study of a Large Outpatient Oncology Practice Database, 2000-2007. Clinical Therapeutics, 31, 2416-2432.

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413